Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
Add Yahoo as a preferred source to see more of our stories on Google. HCC has a high recurrence rate On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, ...
A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the ...
A Prescription Drug User Fee Act target date of April 21, 2025 has been assigned to the application. Findings showed the immunotherapy combination significantly improved overall survival (OS; primary ...
Study targets patients with unresectable or metastatic hepatocellular carcinoma who have progressed following first-line anti-PD-(L)1-based therapy Initiation of the third Phase 2b study of visugromab ...
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...
Patients who are not eligible for surgical resection may or may not be eligible for liver transplant, depending on the extent of their disease, as outlined by the Milan and other criteria above. Some ...
Living a long distance from a treatment center was associated with shorter survival for patients with hepatocellular cancer (HCC), according to research presented at the Gastrointestinal Cancers ...
Please provide your email address to receive an email when new articles are posted on . Survival for people with HCC has improved over the past decade. Much of the improvement has been limited to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results